Bristol-Myers Squibb To Spin-Off Zimmer, Inc.
Advertisement
Bristol-Myers Squibb Company (NYSE: BMY) today announced that it intends to separate its orthopaedics subsidiary Zimmer, Inc. into an independent publicly traded entity, through a tax-free distribution to Bristol-Myers Squibb shareholders.
Divestiture of Zimmer is an element in Bristol-Myers Squibb’s stated strategy of focusing attention and resources on its Medicines businesses.
Bristol-Myers Squibb expects to establish Zimmer as an independent publicly traded company by the end of the third quarter of 2001.
Most read news
Organizations
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Sanofi-aventis enters the Dow Jones Sustainability World Indexes (DJSI World)

Material Scientist wins European Science Slam Championship - Aniruddha Dutta, doctoral student at the Max-Planck-Institut für Eisenforschung, wins championship in Vienna
Degussa: Further Development of Silica-Silane Technology
Heckmann to become President & CEO of Chiral Technologies Inc.

Electronic skin: multisensory hybrid material - Even more sensitive than a human fingertip
